Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved OTC

3

Other

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Cell membrane

1

vasoconstriction

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

3

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1921

2

1903

1

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Chronic obstructive pulmonary disease

2

Cystic fibrosis

2

Hypocalcemia

2

Unknown

2

Itching

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

3

Palliative

2

Curative

1

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Moissan, H.

2

Burow, K.A.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

4

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

4

CODEX ALIMENTARIUS (GSFA)

4

ECHA (EC/EINECS)

4

EPA CompTox

4

FDA UNII

4

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

4

All Match

Any Match

Exclude Selected

Exclude Selected

Search results for "JECFA|Functional Classification|FIRMING AGENT" in comments (approximate match)

Showing 1 - 4 of 4 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

CALCIUM SULFATE ANHYDROUS

E934B3V59H

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

Chronic obstructive pulmonary disease

Cystic fibrosis

Calcium lactate is the salt that consists of two lactate anions for each calcium cation (Ca2+); this salt is used as a calcium supplement to treat hypocalcemia. However, as a source of free calcium, this salt is less convenient than calcium citrate. ...

Calcium lactate inhalation powder also called as PUR118 participated in phase I clinical trials to determine whether this formulation was safe and tolerable in a population of subjects with Cystic Fibrosis (CF). PUR118 also was used in another clinical trials to evaluate its effect on ozone-induced airway Inflammation in healthy normal volunteers in case of Chronic Obstructive Pulmonary Disease (COPD). The obtained results revealed that PUR118 reduced the severity of acute exacerbations in COPD and CF and had the beneficial impacts on mortality, morbidity, and quality of life in affected individuals. However, both studies were discontinued.

CALCIUM CHLORIDE ANHYDROUS

OFM21057LP

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

Chronic obstructive pulmonary disease

Cystic fibrosis

Calcium lactate is the salt that consists of two lactate anions for each calcium cation (Ca2+); this salt is used as a calcium supplement to treat hypocalcemia. However, as a source of free calcium, this salt is less convenient than calcium citrate. ...

Calcium lactate inhalation powder also called as PUR118 participated in phase I clinical trials to determine whether this formulation was safe and tolerable in a population of subjects with Cystic Fibrosis (CF). PUR118 also was used in another clinical trials to evaluate its effect on ozone-induced airway Inflammation in healthy normal volunteers in case of Chronic Obstructive Pulmonary Disease (COPD). The obtained results revealed that PUR118 reduced the severity of acute exacerbations in COPD and CF and had the beneficial impacts on mortality, morbidity, and quality of life in affected individuals. However, both studies were discontinued.

ALUMINUM SULFATE ANHYDROUS

I7T908772F

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1903

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

vasoconstriction

Conditions:

Burow invented an astringent antiseptic solution of aluminium acetate in water to relieve the itching and inflammation of minor skin irritations. At present the oflicial U. S. P. procedure to made Burow's solution involves the reaction of aluminum su...

lfate, calcium carbonate and acetic acid to form aluminum sub-acetate, also termed basic aluminum acetate. The solution is available as an over-the-counter drug for topical administration, with brand names including Domeboro. Burow's solution has been shown to be effective against chronic suppurative otitis media and otitis externa. It is active against bacteria resulting in damage to the cell wall.

CALCIUM BISULFITE

SNM7K02JP2

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1